Shanghai, China (PRWEB) May 15, 2013
Guilin Pharmaceuticals, the World's first producer of artesunate prequalified by the World Health Organisation as meeting the global body's stringent standards for safety, quality and efficacy, has chalked another first.
The company, which manages the world's largest vertically integrated artemisinin production system, has become the first Chinese company to introduce an SMS-based system for African consumers and patients of its medicines to confirm the authenticity of their Guilin-produced anti-malarials.
Buyers of a wide range of Guilin anti-malarials shall be able to scratch-off a special layer covering a unique ID, which they can then send off in a free text message to a special hotline number for instant feedback on the authenticity of the pack.
The service, which shall initially be available to all 50 million mobile subscribers in Nigeria, before being extended to other African countries, comes in the wake of a massive global outcry about the impact of counterfeiting on the world's malaria situation.
Counterfeiting is believed to be contributing to the emergence and spread of newer, more virulent, drug-resistant malarial parasites that are harder and much more expensive to treat, thus raising the risk of death for many patients around the world.
Guilin's new anti-counterfeiting program integrates the company's extensive, in-house, brand protection measures with the Goldkeys© telecom and cloud computing platform provided by the mPedigree Network [http://www.mPedigree.Net , a global social enterprise working to end the trade in counterfeit medicines in Africa and South Asia. This would be the first time the Goldkeys© technology is being deployed in the Chinese pharmaceutical supply chain. The Goldkeys© protocol has been supported by global technology companies such as Hewlett Packard and Orange Health. Selorm Branttie, Market Strategy Lead at mPedigree Network, described Guilin's adoption of Goldkeys© as "a milestone of remarkable importance in the global fight against malaria."
10 million patients are expected to benefit from the program in the first phase of implementation in the 2013 – 2014 operational year.
Ms. Lily Su, Guilin's Vice President, said: "As a company devoted to the highest standards of technical excellence, we are always keen to emphasise that for us the patient, not science, comes first. Our approach is always to go to every conceivable extent to ensure that those who use our medicines become the central fulcrum around which all our activities turn. This new technology leverages the most empowering device in Africa today – the mobile phone – as an additional layer of a powerful patient-empowerment strategy that includes our safety and quality feedback management system."
About Guilin Pharmaceuticals
Founded in 2008, Guilin Pharmaceutical (Shanghai) Co., Ltd. (GPSC) is a subsidiary of Guilin Pharmaceutical Co., Ltd. as well as a member of Fosun Pharmaceutical Group. Focusing on international market business, Guilin develops, produce and market various kinds of pharmaceutical products, including anti-malarials, and generic pharmaceuticals. Guilin market its products in developing countries, and supply its products to clients all over the world, such as WHO, UNICEF, ICRC, MSF, as well as other governmental, profit- and non-profit organizations. As the only pharmaceutical company GMP pre-qualified by WHO to produce Artemisinin-based therapies, Guilin Pharma has established the most integrated industry chain for this category of malaria medicines across the Globe.